Only DUPIXENT
specifically targets
IL-4 and IL-13
signaling
and is approved for
4 indications.^1,a

To continue to a site, select a condition: Choose Condition

Moderate-to-Severe

Atopic Dermatitis

Now Approved for Ages 6 Months-5 Years

For Patients Ages 6+ Months

Eosinophilic Esophagitis

For Patients Ages 12+ Years, Weighing at Least 40 kg

Moderate-to-Severe

Asthma

For Patients Ages 6+ Years with an Eosinophilic Phenotype or OCS-dependent

Chronic Rhinosinusitis With Nasal Polyposis

For Patients Ages 18+ Years

DUPIXENT is indicated in:

Atopic Dermatitis: for the treatment of adult and pediatric patients aged 6 months and older with moderate‑to‑severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

Asthma: as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate‑to‑severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.

Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP): as an add‑on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis.

Eosinophilic Esophagitis: for the treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE).

^aThe mechanism of dupilumab action has not been definitively established.

Dupixent image

Dupixent image

The DUPIXENT 200 mg and 300 mg Pre-filled Pens are available for your appropriate patients aged 12+ years

Choose a condition to be directed to the correct page

Moderate-to-Severe Atopic Dermatitis

Moderate-to-Severe Asthma

Chronic Rhinosinusitis with Nasal Polyposis

Eosinophilic Esophagitis

ClickTap to Learn More

DUPIXENT MyWay® is a patient support program that can help with the enrollment process, offer
financial assistance for eligible patients, provide one-on-one nursing support, and more.

LEARN ABOUT OUR PATIENT SUPPORT PROGRAM

For more information, call 1-844-DUPIXENT (1-844-387-4936), option 1
Monday-Friday, 8 am -to 9 pm ET

Enroll patients in
DUPIXENT MyWay

Learn how to get your patients started with DUPIXENT MyWay.
Fill out the enrollment form with your patients.

*DUPIXENT MyWay* ENROLLMENT FORMS
FOR DERMATOLOGISTS
English Enrollment Form
Spanish Enrollment Form
FOR ALLERGISTS
Allergist (AD, Asthma, CRSwNP) English Enrollment Form
Allergist (AD, Asthma, CRSwNP) Spanish Enrollment Form
Allergist (EoE) English Enrollment Form
Allergist (EoE) Spanish Enrollment Form
FOR ENT SPECIALISTS/ PULMONOLOGISTS
English Enrollment Form
Spanish Enrollment Form
FOR GASTROENTEROLOGISTS
English Enrollment Form
Spanish Enrollment Form

CoverMyMeds support is available for DUPIXENT

CoverMyMeds provides additional PA process-related support for DUPIXENT. Live support is available at 866-452-5017 or covermymeds.com.

WANT TO LEARN MORE ABOUT DUPIXENT?

CHOOSE A CONDITION

Moderate-to-Severe Atopic Dermatitis

Moderate-to-Severe Asthma

Chronic Rhinosinusitis with Nasal Polyposis

Eosinophilic Esophagitis